Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-04
-
br Development of lorlatinib from crizotinib to a clinical c
2024-10-28
Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
faah inhibitor To validate the identified phosphorylation si
2024-10-28
To validate the identified phosphorylation sites in the mouse heart, we analyzed HEK 293T faah inhibitor transfected with Adrb1 based on the hypothesis that protein residues phosphorylated both in vivo and in vitro are more likely to be physiologically relevant. All of the phosphorylation sites iden
-
In the late s Solvay Pharmaceuticals discontinued
2024-10-28
In the late ‘90s, Solvay Pharmaceuticals discontinued the Phase 2 development of a promising potent and highly selective A1AR antagonist based on the pyrrolopyrimidine scaffold, SLV320 [43] (2, Chart 1, also named derenofylline; Ki hA1AR = 1 nM), for the treatment of acute heart failure [24]. In the
-
br Conclusion br Conflicts of interest br Compliance
2024-10-28
Conclusion Conflicts of interest Compliance with ethical standards Introduction Tuberculosis is one of the leading causes of morbidity and mortality, amongst infectious diseases. India is a high burden country for Tuberculosis. Caused by Mycobacterium tuberculosis, it Phosphoramidon Dis
-
Matsuzaki et al attempted fertility therapy in a year
2024-10-28
Matsuzaki et al. attempted fertility therapy in a 26-year-old female with secondary amenorrhea and 17OHD who was a fccp heterozygote for delF53/54 and the missense mutation H373L, which has cycle supports this theory. Oocyte dysfunction with decreased granulosa cell activity might also contribute
-
The present study has several limitations First the results
2024-10-28
The present study has several limitations. First, the results were obtained using RAW264.7 cells, which are derived from BALB/c mice infected with the Abelson leukemia virus (Raschke et al., 1978). However, these cells, which are a commonly used mouse macrophage cell line, show properties similar to
-
Through activation of the CD
2024-10-28
Through activation of the CD46–GOPC pathway, attenuated/vaccinal MeVs rapidly induce a transient phase of autophagy which then diminishes with no signs of negative regulation and precedes a second autophagy phase related to viral protein synthesis [115]. In sharp contrast, virulent MeVs do not inter
-
When skeletal muscle ages there is an increase in
2024-10-28
When skeletal muscle ages, there is an increase in frailty, which is coincident with a decrease in muscle mass and function—this condition is called sarcopenia (Cruz-Jentoft et al., 2010). It has been shown that one of the major pathways downregulated at the onset of sarcopenia is the mitochondrial
-
The growth of cancer can control
2024-10-28
The growth of cancer can control by inhibiting the rate of cell proliferation or increasing the rate of selective apoptosis and effectiveness of anticancer agents varies according to genetic constitution of cancer. Hence, we investigated the anticancer activity of arginase against different kinds of
-
Finally the comparison between data obtained by antioxidant
2024-10-26
Finally, the comparison between data obtained by antioxidant assays in in vitro cultured cells [11], [12] and in liposomes has disclosed the possibility to choose more confidently “the better phenolipid” of a series of fatty acids esters antioxidant derivatives. Looking at the physical parameters th
-
Detailed analysis of the dose dependence of A effects
2024-10-26
Detailed analysis of the dose dependence of Aβ effects revealed that at low amounts, Aβ can also act as a positive regulator of presynaptic activity, enhancing the neurotransmitter release probability and increasing the neuronal excitability [2]. The facilitator effects of low Aβ dose on excitatory
-
br LO synaptic integrity and memory Interestingly
2024-10-26
12/15LO, synaptic integrity, and memory Interestingly, several groups have found that 12/15LO directly modulates synaptic function. Normandin and colleagues reported that pharmacological inhibition of 12/15LO modulates rat hippocampal long-term depression (LTD), a process by which neuronal synapt
-
The cavity volume of the binding pocket
2024-10-26
The cavity volume of the binding pocket may differ not only between species but also among various AhR/ARNT isoforms within a single species. It is noteworthy that even a single amino pd0325901 substitution within a binding pocket may result in a change in the cavity volume. This, in turn, may affe
-
We have previously shown that the antinociceptive effect of
2024-10-26
We have previously shown that the antinociceptive effect of tramadol, an analgesic that, like paracetamol is able to increase serotonin levels within CNS, is potentiated or antagonized respectively by a 5-HT1A/B nonspecific Parthenolide blockade or activation (Rojas-Corrales et al., 2000). Moreover
-
br Actin at presynapses br
2024-10-26
Actin at presynapses Conclusion Thanks to the recent discovery of rings, hotspots and trails, axonal Zileuton is back in the spotlight. These are exiting times for neuronal cell biologists armed with constantly improving labeling and imaging techniques to observe, quantify and perturb these s
15714 records 59/1048 page Previous Next First page 上5页 5657585960 下5页 Last page